Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|The Oncologist|2015Cited by 114
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesColin F. Spraggs, Martine Piccart, L. S. Williams et al.|The Pharmacogenomics Journal|2017Cited by 22